Systematic review of pemetrexed combined with cisplatin in treatment of advanced lung adenocarcinoma

Zhang Meixia; Xu Ximing; Yu Tinging; Hu Yi; Han Nana; Chen Biao

doi:10.3760/cma.j.issn.1673-4777.2015.03.014

Abstract：Objective To assess the effect of pemetrexed combined with cisplatin in treatment of advanced lung adenocarcinoma.Methods The China National Knowledge Infrastructure (CNKI),Chinese Bio medical Literature Database (CBM),China Science and Technology Journal Database (CSTJ),Wanfang Database,PubMed,Excerpta Medica Database (EMBASE) and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from March 2010 to March 2014 to get the randomized controlled trials of pemetrexed combined with cisplatin treating advanced lung adenocarcinoma,and the Meta-analysis was conducted with RevMan 5.0.ResultsTen randomized controlled trials were included in the systematic review with 437 patients.Among them,the pemetrexed combined with cisplatin for the treatment group included 217 patients; the docetaxel combined with cisplatin included 220 patients.According to the Meta analysis,10 studies showed that the effective rate of short-term treatment with pemetrexed combined with cisplatin for the experimental group was improved compared to the control group; the odds risk(OR) and 95％ confidence interval(CI) was 1.77 (1.18-2.64) (P =0.006).Eight studies showed that in terms of reducing white blood cells,pemetrexed combined with cisplatin reduced the white cell account (OR =0.31,95％ CI:0.19-0.51,P ＜0.000 01).7 studies showed that pemetrexed combined with cisplatin reduced the account of platelet (OR =0.26,95％ CI:0.12-0.59,P =0.001).While in aspect of decreasing hemoglobin,it was not statistically significant between the two groups (OR =0.70,95 ％ CI:0.35-0.1.38,P =0.30).Conclusions The results of systematic review indicate that compared with docetaxel combined with cisplatin,pemetrexed combined with cisplatin not only can improve the effective rate of short-term treatment,but also can reduce adverse reactions.